While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...

If anything, Charles Barkley will answer whatever questions you ask him. The “Inside the NBA” analyst was in attendance at the Regions Tradition Celebrity Pro-Am golf tournament at Greystone in Hoover ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Taking semaglutide and liraglutide — a lesser-known active ingredient — medications for weight loss cut their consumption by nearly two-thirds in just four months. At such a critical moment in US ...

Ozempic side effects are a hot topic but don’t panic – our experts are here to help. Here’s what to expect and how to ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...

Novo Nordisk (NYSE: NVO) has entered into a collaboration and licensing agreement with U.S.-based biotech firm Septerna ...

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...

People who take Wegovy appear to be at greater risk for hair loss, according to an early study that hasn't yet been ...

Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.